Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 6Recruiting 2Not yet recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 2Tumor-Agnostic 1Sarcoma 1

Conditions

NSCLC 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 63Cisplatin 40Pemetrexed 38Drug Therapy 37osimertinib 22anlotinib 22Etoposide 20tislelizumab 17Radiotherapy 17Paclitaxel 17Surgical Procedures, Operative 16pembrolizumab 15toripalimab 14130-nm albumin-bound paclitaxel 14aflutinib 13Docetaxel 13Bevacizumab 12sintilimab 10Specimen Handling 10Magnetic Resonance Spectroscopy 10Injections 9durvalumab 8cemiplimab 8Radiosurgery 8Platinum 8PM 01183 8Immunotherapy 8atezolizumab 7Platinum Compounds 7Blood Specimen Collection 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × surufatinib × Thoracic × Clear all
NCT07609121 2026-05-27

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC

Sun Yat-sen University

Phase 2 Not yet recruiting
160 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06414915 2024-05-16

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

National Cancer Center, China

Phase 2 Not yet recruiting
29 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡